Functional Connectivity in Virally Suppressed Patients with HIV-Associated Neurocognitive Disorder: A Resting-State Analysis

REFERENCES

1. 1.↵
   2. Heaton RK,
   3. Clifford DB,
   4. Franklin DR Jr., et al

   ; CHARTER Group. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 2010;75:2087–96 doi:10.1212/WNL.0b013e318200d727 pmid:21135382

   Abstract/FREE Full Text
2. 2.↵
   2. Heaton RK,
   3. Franklin DR,
   4. Ellis RJ, et al

   ; CHARTER Group; HNRC Group. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 2011;17:3–16 doi:10.1007/s13365-010-0006-1 pmid:21174240

   CrossRefPubMedWeb of Science
3. 3.↵
   2. Mothobi NZ,
   3. Brew BJ

   . Neurocognitive dysfunction in the highly active antiretroviral therapy era. Curr Opin Infect Dis 2012;25:4–9 doi:10.1097/QCO.0b013e32834ef586 pmid:22156897

   CrossRefPubMed
4. 4.↵
   2. Cysique LA,
   3. Brew BJ

   . Prevalence of non-confounded HIV-associated neurocognitive impairment in the context of plasma HIV RNA suppression. J Neurovirol 2011;17:176–83 doi:10.1007/s13365-011-0021-x pmid:21416169

   CrossRefPubMed
5. 5.↵
   2. Brew BJ

   . Evidence for a change in AIDS dementia complex in the era of highly active antiretroviral therapy and the possibility of new forms of AIDS dementia complex. AIDS 2004;18(suppl 1):S75–78 pmid:15075501

   CrossRefPubMedWeb of Science
6. 6.↵
   2. Woods SP,
   3. Moore DJ,
   4. Weber E, et al

   . Cognitive neuropsychology of HIV-associated neurocognitive disorders. Neuropsychol Rev 2009;19:152–168 doi:10.1007/s11065-009-9102-5 pmid:19462243

   CrossRefPubMed
7. 7.↵
   2. Chang L,
   3. Tomasi D,
   4. Yakupov R, et al

   . Adaptation of the attention network in human immunodeficiency virus brain injury. Ann Neurol 2004;56:259–72 doi:10.1002/ana.20190 pmid:15293278

   CrossRefPubMedWeb of Science
8. 8.↵
   2. Chang L,
   3. Yakupov R,
   4. Nakama H, et al

   . Antiretroviral treatment is associated with increased attentional load-dependent brain activation in HIV patients. J Neuroimmune Pharmacol 2008;3:95–104 doi:10.1007/s11481-007-9092-0 pmid:18247124

   CrossRefPubMed
9. 9.↵
   2. Foryt P,
   3. Wang X,
   4. Ochs R, et al

   . Diminished resting-state functional connectivity in lateral occipital cortex in early HIV infection. In: Proceedings of the Annual Meeting of the International Society for Magnetic Resonance in Medicine, Montreal, Quebec, Canada. May 6–13, 2011;19:4163
10. 10.↵
    2. Thomas JB,
    3. Brier MR,
    4. Snyder AZ, et al

    . Pathways to neurodegeneration: effects of HIV and aging on resting-state functional connectivity. Neurology 2013;80:1186–93 doi:10.1212/WNL.0b013e318288792b pmid:23446675

    Abstract/FREE Full Text
11. 11.↵
    2. Ipser JC,
    3. Brown GG,
    4. Bischoff-Grethe A, et al

    ; Translational Methamphetamine AIDS Research Center (TMARC) Group. HIV infection is associated with attenuated frontostriatal intrinsic connectivity: a preliminary study. J Int Neuropsychol Soc 2015;21:203–13 doi:10.1017/S1355617715000156 pmid:25824201

    CrossRefPubMed
12. 12.↵
    2. Guha A,
    3. Wang L,
    4. Tanenbaum A, et al

    . Intrinsic network connectivity abnormalities in HIV-infected individuals over age 60. J Neurovirol 2016;22:80–87 doi:10.1007/s13365-015-0370-y pmid:26265137

    CrossRefPubMed
13. 13.↵
    2. Ann HW,
    3. Jun S,
    4. Shin NY, et al

    . Characteristics of resting-state functional connectivity in HIV-associated neurocognitive disorder. PLoS One 2016;11:e0153493 doi:10.1371/journal.pone.0153493 pmid:27104345

    CrossRefPubMed
14. 14.↵
    2. Antinori A,
    3. Arendt G,
    4. Becker , et al

    . Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007;69:1789–99 doi:10.1212/01.WNL.0000287431.88658.8b pmid:17914061

    Abstract/FREE Full Text
15. 15.↵
    2. Heaton RK

    . Revised Comprehensive Norms for an Expanded Halstead-Reitan Battery: Demographically Adjusted Neuropsychological Norms for African American and Caucasian Adults, Professional Manual. Lutz, Florida: Psychological Assessment Resources; 2004
16. 16.↵
    2. Gates TM,
    3. Cysique LA,
    4. Siefried KJ, et al

    . Maraviroc-intensified combined antiretroviral therapy improves cognition in virally suppressed HIV-associated neurocognitive disorder. AIDS 2016;30:591–600 doi:10.1097/QAD.0000000000000951 pmid:26825032

    CrossRefPubMed
17. 17.↵
    2. Cysique LA,
    3. Maruff P,
    4. Darby D, et al

    . The assessment of cognitive function in advanced HIV-1 infection and AIDS dementia complex using a new computerised cognitive test battery. Arch Clin Neuropsychol 2006;21:185–94 doi:10.1016/j.acn.2005.07.011 pmid:16343841

    CrossRefPubMedWeb of Science
18. 18.↵
    2. Lane T,
    3. Moore D,
    4. Batchelor J, et al

    . Facial emotional processing in HIV infection: relation to neurocognitive and neuropsychiatric status. Neurosychology 2012;26:713–22 doi:10.1037/a0029964 pmid:22984798

    CrossRefPubMed
19. 19.↵
    2. Goebel R,
    3. Esposito F,
    4. Formisano E

    . Analysis of functional image analysis contest (FIAC) data with BrainVoyager QX: from single-subject to cortically aligned group general linear model analysis and self-organizing group independent component analysis. Hum Brain Mapp 2006;27:392–401 doi:10.1002/hbm.20249 pmid:16596654

    CrossRefPubMedWeb of Science
20. 20.↵
    2. Goshtasby A

    . Piecewise linear mapping functions for image registration. Pattern Recog 1986;19:459–66 doi:10.1016/0031-3203(86)90044-0

    CrossRef
21. 21.↵
    2. Weissenbacher A,
    3. Kasess C,
    4. Gerstl F, et al

    . Correlations and anticorrelations in resting-state functional connectivity MRI: a quantitative comparison of preprocessing strategies. Neuroimage 2009;47:1408–16 doi:10.1016/j.neuroimage.2009.05.005 pmid:19442749

    CrossRefPubMedWeb of Science
22. 22.↵
    2. Forman SD,
    3. Cohen JD,
    4. Fitzgerald M, et al

    . Improved assessment of significant activation in functional magnetic resonance imaging (fMRI): use of a cluster-size threshold. Magn Reson Med 1995;33:636–47 doi:10.1002/mrm.1910330508 pmid:7596267

    CrossRefPubMedWeb of Science
23. 23.↵
    2. Bressler SL,
    3. Menon V

    . Large-scale brain networks in cognition: emerging methods and principles. Trends Cogn Sci 2010;14:277–90 doi:10.1016/j.tics.2010.04.004 pmid:20493761

    CrossRefPubMedWeb of Science
24. 24.↵
    2. Kallianpur KJ,
    3. Kirk GR,
    4. Sailasuta N, et al

    . Regional cortical thinning associated with detectable levels of HIV DNA. Cereb Cortex 2012;22:2065–75 doi:10.1093/cercor/bhr285 pmid:22016479

    CrossRefPubMedWeb of Science
25. 25.↵
    2. Gongvatana A,
    3. Harezlak J,
    4. Buchthal S, et al

    ; HIV Neuroimaging Consortium. Progressive cerebral injury in the setting of chronic HIV infection and antiretroviral therapy. J Neurovirol 2013;19:209–18 doi:10.1007/s13365-013-0162-1 pmid:23613008

    CrossRefPubMed
26. 26.↵
    2. Amboni M,
    3. Tessitore A,
    4. Esposito F, et al

    . Resting-state functional connectivity associated with mild cognitive impairment in Parkinson's disease. J Neurol 2015;262:425–34 doi:10.1007/s00415-014-7591-5 pmid:25428532

    CrossRefPubMed
27. 27.↵
    2. Dennis EL,
    3. Thompson MP

    . Functional brain connectivity using fMRI in aging and Alzheimer's disease. Neuropsychol Rev 2014;24:49–62 doi:10.1007/s11065-014-9249-6 pmid:24562737

    CrossRefPubMed
28. 28.↵
    2. Liu C,
    3. Li C,
    4. Yin X, et al

    . Abnormal intrinsic brain activity patterns in patients with subcortical ischemic vascular dementia. PLoS One 2014;9:e87880 doi:10.1371/journal.pone.0087880 pmid:24498389

    CrossRefPubMed
29. 29.↵
    2. Castellazzi G,
    3. Palesi ,
    4. Casiraghi L, et al

    . Patterns of altered functional connectivity in Alzheimer disease and vascular dementia. In: Proceedings of the Annual Meeting and Exhibition of the International Society for Magnetic Resonance in Medicine, Toronto, Ontario. Canada. May 30–June 5, 2015
30. 30.↵
    2. Brier MR,
    3. Wu Q,
    4. Tanenbaum AB, et al

    . Effect of HAART on brain organization and function in HIV-negative subjects. J Neuroimmune Pharmacol 2015;10:517–21 doi:10.1007/s11481-015-9634-9 pmid:26446778

    CrossRefPubMed
31. 31.↵
    2. Marra CM,
    3. Zhao Y,
    4. Clifford DB, et al

    ; Clinical Trials Group 736 Study Team. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 2009;23:1359–66 doi:10.1097/QAD.0b013e32832c4152 pmid:19424052

    CrossRefPubMedWeb of Science
32. 32.↵
    2. Bogoch II,
    3. Davis BT,
    4. Venna N

    . Reversible dementia in a patient with central nervous system escape of human immunodeficiency virus. J Infect 2011;63:236–39 doi:10.1016/j.jinf.2011.05.011 pmid:21658774

    CrossRefPubMedWeb of Science